Delivery Order SPE2DB22D2206-SPE2DB25FJB37
- Not listed
- The Defense Logistics Agency awarded a $14,518.84 delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 ml pens on July 15, 2025, with completion scheduled for July 16, 2025. This competitive award carries firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate office in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 30, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pens at a ceiling value of $1,525.20. This competitively awarded, non-set-aside contract represents a firm fixed-price delivery order with performance to be completed by July 1, 2025, with fulfillment occurring at AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order falls under the company's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $1,306.78 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound 5 mg/0.5 mL pens. This competitive award, with a completion date of July 30, 2025, represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply arrangements with the federal government. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania location, where the company operates as a major...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $1,525.20 on August 21, 2025, for the supply of Zepbound 10 mg/0.5 mL pens with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $65,338 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Zepbound 15 mg/0.5 mL pens. This competitively awarded contract, which carries a completion date of September 24, 2025, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child delivery order under a larger contract vehicle, this award leverages AmerisourceBergen's established relationship with...
- The Defense Logistics Agency awarded a delivery order valued at $2,102.31 to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pens on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania location. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.74 to AmerisourceBergen Drug Corp for Zepbound 15 mg/0.5 ml pens on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of pharmaceutical supply services under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pens valued at $5,152.16. This competitively awarded, firm fixed-price delivery order was issued on July 24, 2025, with an ultimate completion date of July 25, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $6,614.56 to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pens. This competitive, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion vehicle extending through December 2026. The product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pens with a ceiling value of $2,287.74. This is a firm fixed-price delivery order under a non-set-aside competitive procurement. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location, with an ultimate completion date of September 26, 2025. This delivery order represents a child contract under AmerisourceBergen's...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJB37Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $11,640.30 to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pens. This firm fixed-price contract, which is a child order under a larger contract vehicle, will be fulfilled from the vendor's location in Conshohocken, Pennsylvania, with an ultimate completion date of July 25, 2025. The award was made through open competition with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, fulfills this delivery order as part of its extensive role supporting federal medical procurement. The company holds a significant $999,999,999 Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX) through December 2026, which serves as the primary vehicle enabling the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This delivery order for Zepbound, a diabetes medication, exemplifies the company's ongoing capacity to meet federal healthcare requirements across multiple therapeutic domains for military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.6k | 7/24/25 |